Jonathan Bromberg, MD
Transplant Surgery · Baltimore, MDNPI 1497721294
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,673 of the $37,883 with a category attached, or 96.8%. 8 manufacturers reported payments, led by Pfizer at 55.9% of the total. Reporting peaked in 2022 at $18,840 and has fallen 83.9% since, to $3,029 in 2025.
Across 19 payments — averaging $1993.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$21K
- Sanofi-aventis U.S. LLC$9K
- Jazz Pharmaceuticals Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Immucor, Inc.$1K
- Regeneron$1K
- plus $990 from 2 others
Across 7 payments — averaging $5622.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29K
- Astellas Pharma Global Development$10K
What the payments were for
- Consulting fees$36,67397%
- Travel & lodging$9803%
- Food & beverage$2311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $21,184 |
| Sanofi-aventis U.S. LLC | 6 | $8,985 |
| Jazz Pharmaceuticals Inc. | 2 | $2,200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,055 |
| Immucor, Inc. | 1 | $1,350 |
| Regeneron | 1 | $1,120 |
| CSL Behring | 1 | $974 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$8,950
- DEFITELIO$2,200
How this compares
Too few transplant surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in Baltimore
- Chandra BhatiBaltimore$168K
- Robert MontgomeryBaltimore$159K
- Jospeph ScaleaBaltimore$8K
- Russell WessonBaltimore$5K
- Raphael MeierBaltimore$5K
- Benjamin PhilosopheBaltimore$5K
- Saad MalikBaltimore$2K
- Daniel MalufBaltimore$2K
- Jordan PydaBaltimore$871
- Niraj DesaiBaltimore$624
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.